Fig. 3From: Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus other treatment regimens in the chinese type 2 diabetes patientsThe acceptability of IDegLira based on QALE based on DUAL I China (a) compared with liraglutide, (b) compared with degludec. QALE ,quality-adjusted life expectancyBack to article page